HIV/AIDS
RSSArticles
-
Study: STIs Can Affect State Medicaid Budgets
Screening and treatment of STIs can cost states tens of millions of dollars in Medicaid budgets, but public health activities to prevent STIs can help reduce these costs, according to a new study.
-
Intervention Reduces Positive STI Tests and Increases Condom Use
A culturally tailored intervention for a particularly vulnerable group of Black women has reduced the odds of testing positive for a sexually transmitted infection and increased condom use in vaginal or anal intercourse, the authors of a recent study found.
-
Fewer Tests, Possible Increases in Sexually Transmitted Infections During Pandemic
Public health officials still do not know the full effect of the pandemic on the incidence of sexually transmitted infections (STIs) in the United States. The COVID-19 pandemic disrupted STI testing. It is unknown if people engaged in risky behavior during various regional and national shutdowns.
-
Cabotegravir Extended-Release and Rilpivirine Injectable Suspension (Cabenuva) and Cabotegravir Tablets (Vocabria)
Cabotegravir/rilpivirine (CAB/RPV) should be prescribed to treat HIV-1-infected adults. This combination should replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen with no history of treatment failure and no known or suspected resistance to ether CAB or RPV.
-
Educational Sessions for Women with Opioid Use Disorder Improve Engagement
A Maine family planning clinic launched a program to reach women who experience barriers to reproductive healthcare, counseling, and testing for sexually transmitted infections. The program focused on outreach, sending an educator to various locations and providing an educational session for women who are especially vulnerable, including those who use opioids.
-
STI Testing Kits Are a Useful Tool During Pandemic
The authors of a recent study show it is feasible for providers to send patients at-home testing kits for sexually transmitted infections and expect a majority to be returned with samples.
-
Fostemsavir Extended-Release Tablets (Rukobia)
Fostemsavir is indicated, with other antiretrovirals, to treat HIV-1 infections in heavily treatment-experienced adults with multidrug-resistant HIV-1 infections who are failing current regimens.
-
Study: Copper IUDs Do Not Appear to Prevent Implantation or Increase HIV Risk
For decades, clinicians and the public assumed that copper intrauterine devices (IUDs) prevented pregnancy by preventing implantation. There also was fear that IUDs could increase a woman’s risk of HIV infection. Results of a new study suggested these assumptions are incorrect.
-
Scientists Make Important Step Toward HIV Cure
In two separate papers, scientists have documented how their efforts reversed HIV and simian immunodeficiency virus latency in two animal models. Findings indicated progress toward an HIV cure.
-
Generic Pre-Exposure Prophylaxis Set to Debut
Pre-exposure prophylaxis (PrEP), which consists of the anti-HIV drugs emtricitabine and tenofovir disoproxil fumarate (TDF/FTC, brand name Truvada), is recommended as a first-line resource in HIV prevention. A generic version of the drug combination is set to be released in 2020, which could expand access to PrEP in the United States.